Search
Valproate bismuth
go.drugbank.com/drugs/DB13910ApprovedValproate bismuth is available in Canada in the over-the-counter medication Neo-Laryngobis.
Artemether
go.drugbank.com/drugs/DB06697ApprovedInvestigationalArtemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of Plas...
Fish oil
go.drugbank.com/drugs/DB13961ApprovedInvestigationalNutraceuticalFish oil is a component of SMOFLIPID, which was FDA approved in July 2016. … More commonly, fish oil refers to the omega-3-fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) [FDA Label].
Mixtures: SMOFKABIVEN EF, Shine Fish Oil + Natural Vitamin EChromium
go.drugbank.com/drugs/DB11136ApprovedInvestigationalChromium chloride is available as an intravenous injection for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN) [FDA Label].
Mixtures: Calcium With Mg Zn Mn Cu CR Si and Vit. C & DPancrelipase amylase
go.drugbank.com/drugs/DB11065ApprovedInvestigational[L2509] The amylases are enzymes that help in the chemical process of digestion by hydrolizing starch into more available saccharide forms. … [L2512] The pancrelipase mixture, including pancrelipase amylase, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510]
Mixtures: KREON MIKRO 5000 IU MINIMIKROSFER,Udenafil
go.drugbank.com/drugs/DB06267ApprovedIt is not yet approved for use in the U.S., E.U., or Canada. … Udenafil is a new phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). It has been approved in South Korea and will be marketed under the brand name Zydena.
Amiloride
go.drugbank.com/drugs/DB00594ApprovedInvestigational(From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705)
Mixtures: Nu-amilzide 5/50 Mg TabSiponimod
go.drugbank.com/drugs/DB12371ApprovedInvestigationalIt was approved by the FDA on March 26, 2019 [L5792] and by Health Canada on February 20, 2020. … [L12171] This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA
Tozinameran
go.drugbank.com/drugs/DB15696ApprovedInvestigational[L15027] On December 11, 2020, the FDA issued an Emergency Use Authorization (EUA) based on 95% efficacy in clinical trials and a similar safety profile to other viral vaccines over a span of approximately … FDA on July 13, 2020.